NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
Findings Presented at ATS 2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 16, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their
View HTML
Toggle Summary Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
Decipher Prostate test specifically cited for its extensive clinical evidence, including from multiple phase 3 randomized trials in high-risk prostate cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that an updated clinical
View HTML
Toggle Summary Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
Findings to Focus on Ability of Immunoscore IC Test to Predict Efficacy of Immune Checkpoint Inhibitors in Patients with NSCLC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 12, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that six abstracts demonstrating the ability of its genomic and
View HTML
Toggle Summary Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 4, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new consensus data from a survey of leading breast cancer oncologists in Europe suggest the importance of gene expression profile (GEP) testing in guiding treatment decisions for women
View HTML
Toggle Summary Veracyte Announces First Quarter 2022 Financial Results
Grew Total Revenue to $67.8 million , an Increase of 85% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 3, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2022 .
View HTML
Toggle Summary Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
Review article and commentary in AnnalsATS reinforce clinical utility of genomic test to improve confidence in IPF diagnosis, in conjunction with HRCT and clinical factors SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated
View HTML
Toggle Summary Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
Findings Provide New Insights into Genomic Underpinnings of Prostate and Bladder Cancers SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 28, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting new data on the genomic underpinnings of prostate and bladder
View HTML
Toggle Summary Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 26, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new, expanded data demonstrating the performance of the company’s non-invasive Percepta   Nasal Swab test in the evaluation of potentially cancerous lung nodules will be presented at
View HTML
Toggle Summary Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2022 after the close of market on Tuesday, May 3, 2022 . Company management will host a conference call and webcast to discuss
View HTML
Toggle Summary Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 1, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a presentation at Cowen’s 42 nd Annual Health Care Conference on March 8 th at
View HTML